1 ANNEX, Regulation (EU) 2022/692

In forcesince 16 Feb 2022

Annex VI to Regulation (EC) No 1272/2008 is amended as follows:

(1)

in Part 3, Table 3 is amended as follows:

(a)

the following entries are inserted:

Index No | Chemical Name | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M- factors and ATE | Notes

Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s)

‘014-052-00-7 | silanamine, 1,1,1-trimethyl-N-(trimethylsilyl)-, hydrolysis products with silica; pyrogenic, synthetic amorphous, nano, surface treated silicon dioxide | 272-697-1 | 68909-20-6 | STOT RE 2 | H373 (lungs) (inhalation) |

GHS08

Wng

H373 (lungs) (inhalation) | EUH066’ | |

‘035-005-00-7 | ammonium bromide | 235-183-8 | 12124-97-9 |

Repr. 1B

Lact.

STOT SE 3

STOT RE 1

Eye Irrit. 2

H360FD

H362

H336

H372 (nervous system)

H319

GHS08

GHS07

Dgr

H360FD

H362

H336

H372 (nervous system)

H319’

‘050-032-00-4 | dibutyltin bis(2-ethylhexanoate) | 220-481-2 | 2781-10-4 |

Muta. 2

Repr. 1B

STOT RE 1

H341

H360FD

H372 (immune system)

GHS08

Dgr

H341

H360FD

H372 (immune system)’

‘050-033-00-X | dibutyltin di(acetate) | 213-928-8 | 1067-33-0 |

Muta 2

Repr. 1B

STOT RE 1

H341

H360FD

H372 (immune system)

GHS08

Dgr

H341

H360FD

H372 (immune system)’

‘052-001-00-0 | tellurium | 236-813-4 | 13494-80-9 |

Repr. 1B

Lact.

H360Df

H362

GHS08

Dgr

H360Df

H362’

‘052-002-00-6 | tellurium dioxide | 231-193-1 | 7446-07-3 |

Repr. 1B

Lact.

H360Df

H362

GHS08

Dgr

H360Df

H362’

‘056-005-00-3 | barium diboron tetraoxide | 237-222-4 | 13701-59-2 |

Repr. 1B

Acute Tox. 4

Acute Tox. 3

H360FD

H332

H301

GHS08

GHS06

Dgr

H360FD

H332

H301

inhalation:

ATE = 1,5 mg/L (dusts or mists)

oral:

ATE = 100 mg/kg bw’

‘601-097-00-8 | Propylbenzene | 203-132-9 | 103-65-1 |

Flam. Liq. 3

Asp. Tox. 1

STOT SE 3

Aquatic Chronic 2

H226

H304

H335

H411

GHS02

GHS08

GHS07

GHS09

Dgr

H226

H304

H335

H411’

‘603-243-00-6 | 2,2-dimethylpropan-1-ol, tribromo derivative; 3-bromo-2,2-bis(bromomethyl)propan-1-ol | 253-057-0 | 36483-57-5; 1522-92-5 |

Carc. 1B

Muta. 2

H350

H341

GHS08

Dgr

H350

H341’

‘604-096-00-0 | piperonyl butoxide (ISO); 2-(2-butoxyethoxy)ethyl 6-propylpiperonyl ether | 200-076-7 | 51-03-6 |

STOT SE 3

Eye Irrit. 2

Aquatic Acute 1

Aquatic Chronic 1

H335

H319

H400

H410

GHS07

GHS09

Wng

H335

H319

H410

EUH066 |

M = 1

M = 1’

‘604-097-00-6 | 2,4,6-tri-tert-butylphenol | 211-989-5 | 732-26-3 |

Repr. 1B

Acute Tox. 4

STOT RE 2

Skin Sens. 1B

H360D

H302

H373 (liver)

H317

GHS08

GHS07

Dgr

H360D

H302

H373 (liver)

H317

oral:

ATE = 500 mg/kg bw’

‘604-098-00-1 | 4,4'-sulphonyldiphenol; bisphenol S | 201-250-5 | 80-09-1 | Repr. 1B | H360FD |

GHS08

Dgr

H360FD’ | | |

‘606-153-00-5 | benzophenone | 204-337-6 | 119-61-9 | Carc. 1B | H350 |

GHS08

Dgr

H350’ | | |

‘606-154-00-0 | quinoclamine (ISO); 2-amino-3-chloro-1,4-naphthoquinone | 220-529-2 | 2797-51-5 |

Carc. 2

Repr. 2

Acute Tox. 4

STOT RE 2

Eye Irrit. 2

Skin Sens. 1A

Aquatic Acute 1

Aquatic Chronic 1

H351

H361d

H302

H373 (blood system, kidneys)

H319

H317

H400

H410

GHS08

GHS07

GHS09

Wng

H351

H361d

H302

H373 (blood system, kidneys)

H319

H317

H410

oral:

ATE = 500 mg/kg bw

M = 10

M = 10’

‘607-756-00-6 | exo-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl acrylate; isobornyl acrylate | 227-561-6 | 5888-33-5 | Skin Sens. 1A | H317 |

GHS07

Wng

H317’ | | |

‘607-757-00-1 | daminozide (ISO); 4-(2,2-dimethylhydrazino)-4-oxobutanoic acid; N-dimethylaminosuccinamic acid | 216-485-9 | 1596-84-5 | Carc. 2 | H351 |

GHS08

Wng

H351’ | | |

‘607-758-00-7 | 4,4'-oxydi(benzenesulphonohydrazide) | 201-286-1 | 80-51-3 |

Self-react. D

Aquatic Acute 1

Aquatic Chronic 1

H242

H400

H410

GHS02

GHS09

Dgr

H242

H410

M = 1

M = 1’

‘607-759-00-2 | toluene-4-sulphonohydrazide | 216-407-3 | 1576-35-8 | Self-react. D | H242 |

GHS02

Dgr

H242’ | | |

‘607-760-00-8 | 2-[N-ethyl-4-[(5-nitrothiazol-2-yl)azo]-m-toluidino]ethyl acetate; C.I. Disperse Blue 124 | 239-203-6 | 15141-18-1 | Skin Sens. 1A | H317 |

GHS07

Wng

H317 | | Skin Sens. 1A; H317: C ≥ 0,001 %’ |

‘607-761-00-3 | Perfluoroheptanoic acid; tridecafluoroheptanoic acid | 206-798-9 | 375-85-9 |

Repr. 1B

STOT RE 1

H360D

H372 (liver)

GHS08

Dgr

H360D

H372 (liver)’

‘607-762-00-9 | methyl N-(isopropoxycarbonyl)-L-valyl-(3RS)-3-(4-chlorophenyl)-β-alaninate; valifenalate | - | 283159-90-0 |

Carc. 2

Aquatic Chronic 2

H351

H411

GHS08

GHS09

Wng

H351

H411’

‘607-763-00-4 | 6-[C12-18-alkyl-(branched, unsaturated)-2,5-dioxopyrrolidin-1-yl]hexanoic acid, sodium and tris(2-hydroxyethyl)ammonium salts | - | - |

Repr. 1B

Eye Irrit. 2

H360FD

H319

GHS08

GHS07

Dgr

H360FD

H319’

‘607-764-00-X | 6-[(C10-C13)-alkyl-(branched, unsaturated)-2,5-dioxopyrrolidin-1-yl]hexanoic acid | - | 2156592-54-8 |

Repr. 1B

Eye Irrit. 2

H360FD

H319

GHS08

GHS07

Dgr

H360FD

H319’

‘607-765-00-5 | 6-[C12-18-alkyl-(branched, unsaturated)-2,5-dioxopyrrolidin-1-yl]hexanoic acid | - | - | Repr. 1B | H360FD |

GHS08

Dgr

H360FD’ | | |

‘613-341-00-0 | clofentezine (ISO); 3,6-bis(o-chlorophenyl)-1,2,4,5-tetrazine | 277-728-2 | 74115-24-5 | Aquatic Chronic 1 | H410 |

GHS09

Wng

H410 | | M = 1’ |

‘613-342-00-6 | theophylline; 1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione | 200-385-7 | 58-55-9 | Repr. 1B | H360D |

GHS08

Dgr

H360D’ | | |

‘613-343-00-1 | pyridalyl (ISO); 2,6-dichloro-4-(3,3-dichloroallyloxy)phenyl 3-[5-(trifluoromethyl)-2-pyridyloxy]propyl ether | - | 179101-81-6 |

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H317

H400

H410

GHS07

GHS09

Wng

H317

H410

M = 1000

M = 100’

‘613-344-00-7 | Pyridine-2-thiol 1-oxide, sodium salt; pyrithione sodium; sodium pyrithione |

223-296-5;

240-062-8

3811-73-2;

15922-78-8

Acute Tox. 3

Acute Tox. 3

Acute Tox. 4

STOT RE 1

Skin Irrit. 2

Eye Irrit. 2

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 2

H331

H311

H302

H372 (nervous system)

H315

H319

H317

H400

H411

GHS06

GHS08

GHS09

Dgr

H331

H311

H302

H372 (nervous system)

H315

H319

H317

H410

EUH070 |

inhalation:

ATE = 0,5 mg/L (dusts or mists)

dermal:

ATE = 790 mg/kg bw

oral:

ATE = 500 mg/kg bw

M = 100’

‘613-345-00-2 |

1,3,5-triazine-2,4,6-triamine;

melamine

203-615-4 | 108-78-1 |

Carc. 2

STOT RE 2

H351

H373 (urinary tract)

GHS08

Wng

H351

H373 (urinary tract)’

‘615-046-00-2 | 1,3-bis(1-isocyanato-1-methylethyl)benzene; [m-TMXDI] | 220-474-4 | 2778-42-9 |

Resp. Sens. 1

Skin Sens. 1A

H334

H317

GHS08

Dgr

H334

H317’

‘615-047-00-8 | 1,3-bis(isocyanatomethyl)benzene; [m-XDI] | 222-852-4 | 3634-83-1 |

Resp. Sens. 1

Skin Sens. 1A

H334

H317

GHS08

Dgr

H334

H317

Skin Sens. 1A; H317: C ≥ 0,001 %’ |

‘615-048-00-3 | 2,4,6-triisopropyl-m-phenylene diisocyanate | 218-485-4 | 2162-73-4 |

Resp. Sens. 1

Skin Sens. 1

H334

H317

GHS08

Dgr

H334

H317’

‘615-049-00-9 |

1,5-naphthylene diisocyanate

[containing < 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 μm]

221-641-4 | 3173-72-6 |

STOT SE 3

Skin Irrit. 2

Eye Irrit. 2

Resp. Sens. 1

Skin Sens. 1A

Aquatic Chronic 3

H335

H315

H319

H334

H317

H412

GHS07

GHS08

Dgr

H335

H315

H319

H334

H317

H412’

‘615-050-00-4 |

1,5-naphthylene diisocyanate

[containing ≥ 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 μm]

221-641-4 | 3173-72-6 |

Acute Tox. 2

STOT SE 3

Skin Irrit. 2

Eye Irrit. 2

Resp. Sens. 1

Skin Sens. 1A

Aquatic Chronic 3

H330

H335

H315

H319

H334

H317

H412

GHS06

GHS08

Dgr

H330

H335

H315

H319

H334

H317

H412

inhalation:

ATE = 0,27 mg/L (dusts or mists)’

‘616-237-00-3 | fluopicolide (ISO); 2,6-dichloro-N-[3-chloro-5-(trifluoromethyl)-2-pyridylmethyl]benzamide | - | 239110-15-7 | Repr. 2 | H361d |

GHS08

Wng

H361d’ | | |

‘616-238-00-9 | N-(2-nitrophenyl)phosphoric triamide | 477-690-9 | 874819-71-3 |

Repr. 1B

STOT RE 2

H360Fd

H373 (kidneys)

GHS08

Dgr

H360Fd

H373 (kidneys)’

‘616-239-00-4 | N-(5-chloro-2-isopropylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide; isoflucypram | - | 1255734-28-1 |

Repr. 2

Acute Tox. 4

Skin Sens. 1B

Aquatic Acute 1

Aquatic Chronic 1

H361f

H332

H317

H400

H410

GHS08

GHS07

GHS09

Wng

H361f

H332

H317

H410

inhalation:

ATE = 2,2 mg/L (dusts or mists)

M = 10

M = 1’

‘616-240-00-X | Reaction mass of 3-(difluoromethyl)-1-methyl-N-[(1RS,4SR,9RS)-1,2,3,4-tetrahydro-9-isopropyl-1,4-methanonaphthalen-5-yl]pyrazole-4-carboxamide and 3-(difluoromethyl)-1-methyl-N-[(1RS,4SR,9SR)-1,2,3,4-tetrahydro-9-isopropyl-1,4-methanonaphthalen-5-yl]pyrazole-4-carboxamide [≥ 78 % syn isomers ≤ 15 % anti isomers relative content]; isopyrazam | - | 881685-58-1 |

Carc. 2

Repr. 1B

Skin Sens. 1B

Aquatic Acute 1 Aquatic Chronic 1

H351

H360D

H317

H400

H410

GHS08

GHS07

GHS09

Dgr

H351

H360D

H317

H410

Repr. 1B; H360D:

C ≥ 3 %

M = 10

M = 10’

‘650-058-00-1 | Margosa, ext. [from the kernels of Azadirachta indica extracted with water and further processed with organic solvents] | 283-644-7 | 84696-25-3 |

Repr. 2

Skin Sens. 1

Aquatic Chronic 1

H361d

H317

H410

GHS08

GHS07

GHS09

Wng

H361d

H317

H410

M = 10’ |

(b)

the entries corresponding to index numbers 014-001-00-9; 023-001-00-8; 601-024-00-X; 603-014-00-0; 603-107-00-6; 604-030-00-0; 607-111-00-9; 607-230-00-6; 607-253-00-1; 607-254-00-7; 607-734-00-6; 607-735-00-1; 607-736-00-7; 608-032-00-2; 609-042-00-X; 613-012-00-1; 616-164-00-7 are replaced by the following entries respectively:

Index No | Chemical Name | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M- factors and ATE | Notes

Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s)

‘014-001-00-9 | trichlorosilane | 233-042-5 | 10025-78-2 |

Flam. Liq. 1

Water-react. 1

Acute Tox. 3

Acute Tox. 4

Skin Corr. 1A

Eye Dam. 1

H224

H260

H331

H302

H314

H318

GHS02

GHS06

GHS05

Dgr

H224

H260

H331

H302

H314

EUH014

EUH029

EUH071

inhalation:

ATE = 7,6 mg/L (vapour)

oral:

ATE = 1000 mg/kg bw’

‘023-001-00-8 | divanadium pentaoxide; vanadium pentoxide | 215-239-8 | 1314-62-1 |

Muta. 2

Carc. 1B

Repr. 2

Lact.

Acute Tox. 3

Acute Tox. 2

STOT SE 3

STOT RE 1

Aquatic Chronic 2

H341

H350

H361fd

H362

H301

H330

H335

H372 (respiratory tract, inhalation)

H411

GHS06

GHS08

GHS09

Dgr

H341

H350

H361fd

H362

H301

H330

H335

H372 (respiratory tract, inhalation)

H411

inhalation:

ATE = 0,05 mg/L (dusts or mists)

oral:

ATE = 220 mg/kg bw’

‘601-024-00-X | Cumene | 202-704-5 | 98-82-8 |

Flam. Liq. 3

Carc. 1B

Asp. Tox. 1

STOT SE 3

Aquatic Chronic 2

H226

H350

H304

H335

H411

GHS02

GHS08

GHS07

GHS09

Dgr

H226

H350

H304

H335

H411’

‘603-014-00-0 | 2-butoxyethanol; ethylene glycol monobutyl ether | 203-905-0 | 111-76-2 |

Acute Tox. 3

Acute Tox. 4

Skin Irrit. 2

Eye Irrit. 2

H331

H302

H315

H319

GHS06

Dgr

H331

H302

H315

H319

inhalation:

ATE = 3 mg/L (Vapours)

oral:

ATE = 1200 mg/kg bw’

‘603-107-00-6 | 2-(2-methoxyethoxy)ethanol; diethylene glycol monomethyl ether | 203-906-6 | 111-77-3 | Repr. 1B | H360D |

GHS08

Dgr

H360D | | Repr. 1B; H360D: C ≥ 3 %’ |

‘604-030-00-0 | 4,4'-isopropylidenediphenol; bisphenol A | 201-245-8 | 80-05-7 |

Repr. 1B

STOT SE 3

Eye Dam. 1

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H360F

H335

H318

H317

H400

H410

GHS08

GHS07

GHS05

GHS09

Dgr

H360F

H335

H318

H317

H410

M = 1

M = 10’

‘607-111-00-9 |

2-ethyl-2-[[(1-oxoallyl)oxy]methyl]-1,3-propanediyl diacrylate; 2,2-bis(acryloyloxymethyl)butyl acrylate;

trimethylolpropane triacrylate

239-701-3 | 15625-89-5 |

Carc. 2

Skin Irrit. 2

Eye Irrit. 2

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H351

H315

H319

H317

H400

H410

GHS08

GHS07

GHS09

Wng

H351

H315

H319

H317

H410

M = 1

M = 1

D’

‘607-230-00-6 | 2-ethylhexanoic acid and its salts, with the exception of those specified elsewhere in this Annex | - | - | Repr. 1B | H360D |

GHS08

Dgr

H360D’ | | |

‘607-253-00-1 | cyfluthrin (ISO); α-cyano-4-fluoro-3-phenoxybenzyl-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate | 269-855-7 | 68359-37-5 |

Lact.

Acute Tox. 2

Acute Tox. 2

STOT SE 1

Aquatic Acute 1

Aquatic Chronic 1

H362

H330

H300

H370 (nervous system)

H400

H410

GHS06

GHS08

GHS09

Dgr

H362

H330

H300

H370 (nervous system)

H410

inhalation:

ATE = 0,14 mg/L (dusts or mists)

oral:

ATE = 14 mg/kg bw

M = 1000000

M = 1000000’

‘607-254-00-7 | beta-cyfluthrin (ISO); reaction mass of rel-(R)-cyano(4-fluoro-3-phenoxyphenyl)methyl (1S,3S)-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane-1-carboxylate and rel-(R)-cyano(4-fluoro-3-phenoxyphenyl)methyl (1S,3R)-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane-1-carboxylate | - | 1820573-27-0 |

Lact.

Acute Tox. 2

Acute Tox. 2

STOT SE 1

Aquatic Acute 1

Aquatic Chronic 1

H362

H330

H300

H370 (nervous system)

H400

H410

GHS06

GHS08

GHS09

Dgr

H362

H330

H300

H370 (nervous system)

H410

inhalation:

ATE = 0,081 mg/L (dusts or mists)

oral:

ATE = 11 mg/kg bw

M = 1000000

M = 1000000’

‘607-734-00-6 | pentapotassium 2,2',2",2"',2""-(ethane-1,2-diylnitrilo)pentaacetate | 404-290-3 | 7216-95-7 |

Repr. 1B

Acute Tox. 4

STOT RE 2

Eye Irrit. 2

H360D

H332

H373 (inhalation)

H319

GHS08

GHS07

Dgr

H360D

H332

H373 (inhalation)

H319

Repr. 1B; H360D: C ≥ 3 %

inhalation:

ATE = 1,5 mg/L (dusts or mists)’

‘607-735-00-1 | N-carboxymethyliminobis(ethylenenitrilo)tetra(acetic acid) | 200-652-8 | 67-43-6 |

Repr. 1B

Acute Tox. 4

STOT RE 2

Eye Irrit. 2

H360D

H332

H373 (inhalation)

H319

GHS08

GHS07

Dgr

H360D

H332

H373 (inhalation)

H319

Repr. 1B; H360D: C ≥ 3 %

inhalation:

ATE = 1,5 mg/L (dusts or mists)’

‘607-736-00-7 | pentasodium (carboxylatomethyl)iminobis(ethylenenitrilo)tetraacetate | 205-391-3 | 140-01-2 |

Repr. 1B

Acute Tox. 4

STOT RE 2

H360D

H332

H373 (inhalation)

GHS08

GHS07

Dgr

H360D

H332

H373 (inhalation)

Repr. 1B; H360D: C ≥ 3 %

inhalation:

ATE = 1,5 mg/L (dusts or mists)’

‘608-032-00-2 | acetamiprid (ISO); (1E)-N-[(6-chloropyridin-3-yl)methyl]-N’-cyano-N-methylethanimidamide; (E)-N1-[(6-chloro-3-pyridyl)methyl]-N2-cyano-N1-methylacetamidine | - | 135410-20-7 160430-64-8 |

Repr. 2

Acute Tox. 3

Aquatic Chronic 1

Aquatic Acute 1

H361d

H301

H410

H400

GHS08

GHS06

GHS09

Dgr

H361d

H301

H410

oral:

ATE = 140 mg/kg bw

M = 10

M = 10’

‘609-042-00-X | pendimethalin (ISO); N-(1-ethylpropyl)-2,6-dinitro-3,4-xylidene | 254-938-2 | 40487-42-1 |

Repr. 2

Aquatic Acute 1

Aquatic Chronic 1

H361d

H400

H410

GHS08

GSH09

Wng

H361d

H410

M = 100

M = 10’

‘613-012-00-1 | bentazone (ISO); 3-isopropyl-2,1,3-benzothiadiazine-4-one-2,2-dioxide | 246-585-8 | 25057-89-0 |

Repr. 2

Acute Tox. 4

Eye Irrit. 2

Skin Sens. 1

H361d

H302

H319

H317

GHS08

GHS07

Wng

H361d

H302

H319

H317

oral: ATE = 1600 mg/kg bw’ |

‘616-164-00-7 | dimoxystrobin (ISO); (2E)-2-{2-[(2,5-dimethylphenoxy)methyl]phenyl}-2-(methoxyimino)-N-methylacetamide; (E)-2-(methoxyimino)-N-methyl-2-[α-(2,5-xylyloxy)-o-tolyl]acetamide | | 149961-52-4 |

Carc. 2

Repr. 2

Acute Tox. 4

Aquatic Acute 1

Aquatic Chronic 1

H351

H361d

H332

H400

H410

GHS08

GHS07

GHS09

Wng

H351

H361d

H332

H410

inhalation:

ATE = 1,3 mg/L (dusts or mists)

M = 100

M = 100’

(c)

the entry corresponding to index number 615-007-00-X is deleted.